13 results about "Pulmonary edema" patented technology

This invention discloses a method and related equipment for constructing an ultrasound diagnostic training model for lung diseases. The method includes: acquiring magnetic resonance imaging (MRI) data of the chest of a target subject; performing three-dimensional reconstruction and structural segmentation on the MRI data to generate a three-dimensional anatomical digital model of the lung, including the lung parenchyma, pleura, diaphragm, ribs, and mediastinal structures; optimizing the structure, layering the model, and annotating material properties using three-dimensional modeling software to generate a three-dimensional printing model file; constructing a physical lung training model based on the three-dimensional printing model file using a multi-material three-dimensional printing device, and setting pathological simulation structures in a preset area of ​​the model to simulate the ultrasound imaging characteristics of diseases such as pulmonary consolidation, pleural effusion, pneumothorax, and pulmonary edema. The training model constructed by this invention has a realistic anatomical structure, is reusable, and can present typical lung ultrasound imaging characteristics under real ultrasound equipment.

This invention relates to the field of biopharmaceutical technology, specifically to the application of dichloroacetate in the preparation of drugs for preventing high-altitude pulmonary edema. This invention is the first to propose and verify the application of dichloroacetate in preventing high-altitude pulmonary edema. By administering dichloroacetate to mice via drinking water three days in advance as a preventative measure, the degree of pulmonary edema was reduced, providing new drug selection and experimental evidence for the prevention and treatment of altitude sickness.

The application discloses an anti-hypoxia radix glabra composite solid beverage and a preparation method thereof, and belongs to the technical field of health-care beverages. The anti-hypoxia radix glabra composite solid beverage is prepared from radix glabra of nine years as raw material, and comprises the following steps: screening and cleaning, twice soaking, 80 DEG C segmented cooking, 70 DEG C gradient concentration, and low-temperature drying at 65 DEG C or below to obtain high-activity radix glabra extract; then, the radix glabra extract is mixed with white sugar and 95% edible alcohol according to a mass ratio of 1:2:1, and the mixture is dried at 50 DEG C for 2 hours, granulated for 1 hour to obtain the solid granular beverage. The anti-hypoxia radix glabra composite solid beverage has the advantages of maximizing the retention of anti-hypoxia active ingredients, improving the taste and solubility, and the like. Animal experiments prove that the product can significantly relieve the weight loss, pulmonary edema and brain edema caused by hypoxia, regulate key indexes such as HIF-alpha, EPO, TNF-alpha, IL-6 and SOD, and has no obvious organ toxicity and high safety when taken for a long time. The anti-hypoxia radix glabra composite solid beverage is suitable for industrial production, can be used for developing health-care food for resisting hypoxia and relieving the plateau reaction, and provides a standardized scheme for high-value utilization of radix glabra.

This invention relates to the field of medical data processing technology, specifically to a lung infection status early warning system based on medical big data. The system captures the flow velocity response before and after expiratory pressure regulation, and uses regularized inversion to deconstruct the time-domain signal, which is disturbed by respiratory rate, into a standardized sequence of measured lung unit volumes. Subsequently, it constructs a theoretical distribution benchmark of purely elastic recoil using measured high-pressure data. By constructing a transmission cost matrix reflecting the shear characteristics of non-Newtonian fluids, it uses an optimal transmission algorithm to calculate the optimal transmission strategy that reshapes the theoretical distribution into the measured distribution. Finally, it analyzes the topological entropy and transmission energy consumption of this transmission strategy to extract obstruction features and generate an early warning. This invention utilizes a rheological model to specifically quantify the viscosity and focal distribution of fluid within the airway, effectively differentiating between physical pulmonary edema and biological airway obstruction at an early stage.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

This invention discloses a mitochondrial uncoupling agent prodrug with endothelial cell targeting, its preparation method, and its application, relating to the field of biomedical technology. The prodrug is covalently coupled to a vascular cell adhesion molecule-1 targeting polypeptide (amino acid sequence FAKELMEEFEKW), a reactive oxygen species-sensitive thioacetate linker, and the mitochondrial uncoupling agent OPC-163493. This invention utilizes the active enrichment effect of the targeting polypeptide on inflamed pulmonary vascular endothelial cells, overcoming the off-target defects of non-specific distribution in existing small molecule drugs; simultaneously, it utilizes the specific cleavage characteristics of the thioacetate linker in a microenvironment rich in reactive oxygen species to achieve precise in-situ drug release. This prodrug can effectively reduce mitochondrial reactive oxygen species generation, inhibit endothelial cell apoptosis, significantly reduce pulmonary vascular permeability, and alleviate pulmonary edema, possessing significant clinical application value in the preparation of drugs for treating acute lung injury or acute respiratory distress syndrome.

Use of a pyridine sulfonamide phosphate compound or a pharmaceutical composition comprising the same in the preparation of a drug for treating pulmonary edema. This drug inhibits the NKCC1 target in the lungs through a novel mechanism of action, demonstrating outstanding efficacy in treating pulmonary edema with high safety. It can significantly reduce drug distribution in kidney tissue, thereby reducing adverse effects such as electrolyte disturbances caused by potent diuretics. It holds promise as a novel drug for the clinical treatment of pulmonary edema and has a very broad clinical application prospect.

This invention belongs to the field of biomedicine, specifically relating to a cyclic peptide with dual antioxidant and ACE inhibitory activities and its applications. Addressing the relative lack of bifunctional peptides that simultaneously scavenge reactive oxygen species and inhibit ACE activity, this invention provides a novel cyclic peptide, MEE14, which exhibits strong antioxidant and ACE inhibitory activities, high anti-digestion stability, minimal impact on cell proliferation, low cytotoxicity, and high biosafety. Cyclic peptide MEE14 has significant development value and broad application prospects in the prevention and treatment of high-altitude pulmonary edema, hypoxic hypertension, and other spontaneous hypertension. It can be used in pharmaceuticals, functional foods, and cosmetics related to the prevention or treatment of diseases associated with oxidative stress and excessive activation of the renin-angiotensin system.

This invention discloses an inhibitor of lncRNA Rmst-3 and its application in the preparation of drugs for treating acute lung injury caused by bacterial infection. The study found that lncRNA Rmst-3 is significantly overexpressed in tissues with acute lung injury induced by Gram-negative bacterial infection; it specifically adsorbs miR-1958 as a competitive endogenous RNA, thereby relieving the inhibition of the target gene CD38, leading to activation of the downstream SIRT1 / NF-κB / NLRP3 signaling pathway, triggering macrophage pyroptosis and inflammatory storm. The Rmst-3 inhibitor or miR-1958 mimic provided by this invention can effectively block the above signaling axis, significantly reduce pulmonary edema, hemorrhage, and inflammatory cell infiltration, decrease the bacterial load in lung tissue, and improve the survival rate of individuals with acute lung injury. This invention reveals a new mechanism of ALI pathogenesis, providing new molecular targets and drug strategies for clinical treatment.

A traditional Chinese medicine composition for improving or treating acute lung injury and an application thereof. The traditional Chinese medicine composition is made of the following traditional Chinese medicine raw materials: Areca catechu 12-24 parts, Magnolia officinalis 6-12 parts, Amomum tsao-ko 3-6 parts, Anemarrhena asphodeloides 6-12 parts, Paeonia lactiflora 6-12 parts, Scutellaria baicalensis 6-12 parts, Glycyrrhiza uralensis 3-6 parts, Rheum officinale 6-12 parts, Forsythia suspensa 8-16 parts, Mentha haplocalyx 3-6 parts, Gardenia jasminoides 3-6 parts, Mirabilite 3-6 parts, and Bambusa 5-10 parts. In a mouse animal model experiment, the traditional Chinese medicine composition described herein not only can alleviate the phenomenon of inflammatory cell infiltration in the bronchoalveolar lavage fluid caused by LPS, reduce the inflammatory response, but also can help to improve the lung tissue pathological injury induced by LPS, maintain the alveolar structure integrity, inhibit pulmonary edema, down-regulate the level of inflammatory factors in the bronchoalveolar lavage fluid, and inhibit the expression of inflammatory factors in the lung tissue, thereby improving or treating acute lung injury caused by LPS.

The application relates to application of a peppermint-derived exosome in preparation of a medicine for treating LPS-induced ARDS, and the peppermint-derived exosome is obtained through treatment such as soaking in a PBS solution, wall breaking, differential centrifugation, filtration, ultracentrifugation, sucrose density gradient centrifugation and the like. The peppermint-derived exosome in the application can not only reduce histological damage of lung tissue of LPS-induced ARDS mice, improve pulmonary edema, but also has an anti-inflammatory effect on the lung of the ARDS mice, so that the peppermint-derived exosome can be used for preparing a medicine for treating LPS-induced ARDS.

An inhalation preparation for treating pulmonary edema, comprising a pyridine sulfonamide phosphate compound represented by formula 1 or a pharmaceutically acceptable salt thereof and a cationic guar gum. The cationic guar gum can greatly improve the permeability of the pyridine sulfonamide phosphate compound or the pharmaceutically acceptable salt thereof in a Calu-3 cell model (an in vitro simulation of lung tissue epithelial cell model). The application also provides a preparation method of the inhalation preparation: under normal temperature and pressure, the main drug, the absorption promoter and the freeze-drying excipient are dissolved in water in proportion and are constant volume to the total amount, and are filtered and freeze-dried. The inhalation preparation prepared by the application has strong lung permeability, simple production process and good application prospect.

This invention discloses an enzymatic preparation process for isoquercetin and its application in the preparation of products for improving pulmonary nodules and nourishing the lungs. The method uses rutin as a raw material, hydrolyzing it under the action of rhamnosidase to obtain high-purity isoquercetin; the process is green and efficient. Experiments show that the obtained isoquercetin can significantly reduce the levels of pulmonary inflammatory factors IL6 and TNFα, alleviate pulmonary edema, and improve pathological changes in pulmonary nodules, exhibiting clear lung-nourishing and moisturizing effects. The isoquercetin of this invention can be used to prepare pharmaceutical or health care products for improving pulmonary nodules, alleviating pulmonary inflammation, and nourishing and moisturizing the lungs.